Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

La inhibició de la transmissió adrenèrgica contribueix a la vasodilatació esplàcnica de la hipertensió portal

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 36000
Reference: POST-MIR/CAIX/02/07
Duration: 01/07/2007 - 30/06/2009

CIBER Enfermedades hepáticas y digestivas (CIBEREHD)

IP: Joan Genescà Ferrer
Collaborators: Lluís Palenzuela Díaz, Nuria Raguer Sanz
Funding agency: CIBER Enfermedades Hepáticas y Digestivas
Funding:
Reference: CB06/04/0007
Duration: 01/01/2007 - 31/12/2010

Utilidad de la PCR bacteriana en el diagnostico de la peritonitis bacteriana espontánea del cirrotico.

IP: Joan Genescà Ferrer
Collaborators: Antonio González Fernández
Funding agency: Instituto de Salud Carlos III
Funding: 15205.61
Reference: 01/1390
Duration: 17/07/2001 - 31/12/2002

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Santos Ortega, Alba

Santos Ortega, Alba

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Cañas Perea

Xavier Cañas Perea

Director/a d'Àrea
Clinical Research Development Directorate
Read more
Ruiz Esteve, Fernando

Ruiz Esteve, Fernando

Research technician
Neurovascular Diseases
Read more
Marcos Prieto, Susana

Marcos Prieto, Susana

Research technician
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.